On 12 February 2026, Dr. Toh Tan Boon, Principal Investigator and Head of the Translational Core at the Institute for Digital Medicine (WisDM) and N.1 Institute for Health, delivered an invited talk titled “Functional Precision Oncology: From Living Tumors to Decision-Ready Therapies” at the 3rd Organoid Symposium (Organoid Day 2026), held at NTU Alumni @one-north. Presented by STEMCELL Technologies, IMCB (A*STAR), SCSS and NUS Yong Loo Lin School of Medicine (WisDM and Precision Medicine TRPs), Organoid Day (now in its third year) continues to advance research in organoid technology and clinical applications. Since its launch, the symposium has served as a key platform for sharing research developments, exchanging ideas, and fostering collaboration within Singapore’s growing organoid community.

In his talk, Dr. Toh highlighted WisDM’s integrated functional precision oncology (FPO) framework, which leverages patient-derived tumor model to evaluate therapeutic responses in patients. By combining functional drug testing with computational optimization platforms, this approach aims to generate clinically actionable, decision-ready treatment strategies, particularly for patients with aggressive and treatment-refractory cancers. The symposium reinforced WisDM’s commitment to bridging advanced patient-derived avatars with digital innovation, accelerating the translation of organoid science into meaningful patient impact.